MarketCap
Facebook
X
TelegramQuarterly report 2025-Q2
added 07-31-2025
Bio-Rad Laboratories Net Debt 2011-2026 | BIO
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Bio-Rad Laboratories
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 754 M | 836 M | 800 M | -424 M | -624 M | -221 M | 7.9 M | 51.2 M | -21.7 M | -21.5 M | 22.7 M | 106 M | 271 M | 158 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 836 M | -624 M | 121 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Medical devices industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AxoGen
AXGN
|
21.9 M | $ 31.63 | 2.03 % | $ 1.4 B |  USA |
 |
Acutus Medical
AFIB
|
14.2 M | - | -26.83 % | $ 2.62 M | USA |
 |
Boston Scientific Corporation
BSX
|
8.64 B | $ 95.41 | 0.76 % | $ 140 B | USA |
 |
Abiomed
ABMD
|
-227 M | - | - | $ 17.2 B | USA |
 |
Allied Healthcare Products
AHPI
|
-3.31 M | - | 3.58 % | $ 2.21 M | USA |
 |
GenMark Diagnostics, Inc.
GNMK
|
38.7 M | - | - | $ 1.77 B | USA |
 |
Alphatec Holdings
ATEC
|
442 M | $ 21.25 | 2.36 % | $ 3.04 B | USA |
 |
Axonics Modulation Technologies
AXNX
|
-230 M | - | - | $ 3.31 B | USA |
 |
Apyx Medical Corporation
APYX
|
-10.1 M | $ 3.6 | 2.86 % | $ 125 M | USA |
 |
Cognyte Software Ltd.
CGNT
|
-47.4 M | $ 9.15 | 2.81 % | $ 657 M |  Israel |
 |
Obalon Therapeutics, Inc.
OBLN
|
6.46 M | - | -5.86 % | $ 30.6 M | USA |
 |
Apollo Endosurgery
APEN
|
-22.5 M | - | - | $ 475 M | USA |
 |
CONMED Corporation
CNMD
|
889 M | $ 42.12 | 3.97 % | $ 1.3 B | USA |
 |
Conformis
CFMS
|
-26.2 M | - | - | $ 16.4 M | USA |
 |
BioSig Technologies
BSGM
|
252 K | - | 37.08 % | $ 85.7 M | USA |
 |
Bruker Corporation
BRKR
|
1.91 B | $ 50.6 | 5.18 % | $ 7.54 K | USA |
 |
EDAP TMS S.A.
EDAP
|
-22.8 M | $ 3.48 | 2.35 % | $ 130 M |  France |
 |
Abbott Laboratories
ABT
|
5.26 B | $ 126.37 | 1.76 % | $ 220 B | USA |
 |
Cardiovascular Systems
CSII
|
-64.6 M | - | 0.15 % | $ 844 M | USA |
 |
Cutera
CUTR
|
-140 M | - | -10.19 % | $ 1.99 M | USA |
 |
CryoLife, Inc.
CRY
|
230 M | - | -4.14 % | $ 702 M | USA |
 |
Eargo
EAR
|
-97.8 M | - | - | $ 10.2 M | USA |
 |
Electromed
ELMD
|
-10.5 M | $ 28.03 | 2.34 % | $ 237 M | USA |
 |
Soliton, Inc.
SOLY
|
-31.6 M | - | -1.42 % | $ 435 M | USA |
 |
Hancock Jaffe Laboratories, Inc.
HJLI
|
-9.02 K | - | -1.98 % | $ 98.3 M | USA |
 |
Itamar Medical Ltd.
ITMR
|
-2.3 M | - | 0.03 % | $ 1.58 B | Israel |
 |
Second Sight Medical Products
EYES
|
961 K | - | -0.97 % | $ 54.4 M | USA |
 |
Misonix, Inc.
MSON
|
5.72 M | - | - | $ 462 M | USA |
 |
Neovasc
NVCN
|
-4.95 M | - | - | $ 111 M |  Canada |
 |
Dynatronics Corporation
DYNT
|
1.8 M | - | 14.99 % | $ 929 K | USA |
 |
Intersect ENT, Inc.
XENT
|
50.8 M | - | - | $ 955 M | USA |
 |
InMode Ltd.
INMD
|
-34.8 M | $ 15.27 | 3.18 % | $ 1.21 B | Israel |
 |
IRadimed Corporation
IRMD
|
-52.1 M | $ 98.11 | 2.73 % | $ 1.24 B | USA |
 |
Align Technology
ALGN
|
-925 M | $ 160.18 | 2.66 % | $ 12 B | USA |
 |
OrthoPediatrics Corp.
KIDS
|
31.3 M | $ 18.13 | 3.22 % | $ 418 M | USA |
 |
Accuray Incorporated
ARAY
|
73.7 M | $ 0.89 | 4.38 % | $ 91.5 M | USA |
 |
Avinger
AVGR
|
-16.3 M | - | -20.74 % | $ 369 K | USA |
 |
ClearPoint Neuro
CLPT
|
-16.5 M | $ 14.34 | 2.21 % | $ 388 M | USA |
 |
FONAR Corporation
FONR
|
-42.8 M | $ 18.52 | 0.03 % | $ 121 M | USA |
 |
LivaNova PLC
LIVN
|
130 M | $ 63.29 | 4.37 % | $ 3.43 B |  Britain |
|
LENSAR
LNSR
|
-13.6 M | $ 11.32 | -2.5 % | $ 130 M | USA |
 |
GBS
GBS
|
-4.38 M | - | -0.57 % | $ 7.12 M | USA |
 |
IRIDEX Corporation
IRIX
|
-4.29 M | $ 1.21 | 3.42 % | $ 19.5 M | USA |
 |
Globus Medical
GMED
|
-774 M | $ 90.81 | 4.02 % | $ 12.3 B | USA |
 |
Integra LifeSciences Holdings Corporation
IART
|
529 M | $ 12.56 | 4.58 % | $ 967 M | USA |
 |
Aziyo Biologics
AZYO
|
1.36 M | - | 1.37 % | $ 20.5 M | USA |
 |
Establishment Labs Holdings
ESTA
|
131 M | $ 65.25 | -5.21 % | $ 1.84 B |  Costa-rica |